Aligos Therapeutics Announces Generic Name Approval for Drug ALG-000184
Aligos Therapeutics Announces Generic Name Approval
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a pioneer in biopharmaceuticals dedicated to enhancing patient outcomes, has made a significant breakthrough. The company has received official approval from the United States Adopted Names (USAN) Council for the nonproprietary name of its investigational drug, previously known as ALG-000184. This medication will now be recognized as pevifoscorvir sodium. This designation marks a critical step forward in the treatment of chronic hepatitis B virus (HBV) infections.
The Importance of Generic Drug Names
The USAN Council, which comprises members from esteemed organizations like the FDA and the American Medical Association, has the crucial task of creating simple and distinctive nonproprietary drug names. The establishment of a generic name plays an essential role in ensuring consistent identification of drugs across markets, fostering transparency and ease of communication among healthcare providers worldwide.
Advances in Drug Development
Lawrence Blatt, PhD, MBA, the Chairman and CEO of Aligos, expressed excitement about this milestone. He stated, “The adoption of pevifoscorvir sodium, or pevy, signifies the first generic name associated with a compound developed by Aligos. Our ongoing Phase 2 B-Supreme study continues to advance, and we eagerly anticipate implementing this new name in our communications.” This approval highlights Aligos' dedication to innovation and improving treatment options for liver and viral diseases.
Clinical Progress and Future Studies
Pevifoscorvir sodium was derived from important intellectual property initially licensed from Dr. Raymond Schinazi's lab at Emory University and subsequently optimized by Aligos. As a promising oral small molecule capsid assembly modulator (CAM-E), it has shown potential in effectively addressing chronic HBV. Initial Phase 1 studies have confirmed that the drug is well-tolerated among participants, exhibiting no major safety concerns while also displaying excellent antiviral activity.
Notably, as part of a 96-week Phase 1 study, pevifoscorvir sodium demonstrated sustained reductions in markers such as HBV DNA and RNA. Furthermore, both monotherapy and its combination with Entacavir (ETV) resulted in significant therapeutic benefits. With the backing of regulatory bodies like the FDA and EMA, Aligos is on a promising path forward, with various studies underway and further data expected to be presented soon.
Understanding Aligos Therapeutics
Aligos Therapeutics is not just focused solely on HBV treatment; their mission extends to addressing various liver and viral conditions. Their innovative approach combines rigorous scientific research with a commitment to developing best-in-class therapies. The company is also exploring solutions for metabolic dysfunction-associated steatohepatitis (MASH) and COVID-19 related ramifications. This breadth of focus underscores their ambition in the biotech landscape.
Contacting Aligos for More Information
For individuals interested in learning more about Aligos Therapeutics and its endeavors, comprehensive information is available through their official channels. The company actively encourages inquiries into its clinical developments and ongoing research.
Frequently Asked Questions
What is the new name for ALG-000184?
The investigational drug ALG-000184 will now be known as pevifoscorvir sodium.
What is Aligos Therapeutics focused on?
Aligos Therapeutics specializes in developing therapies for liver and viral diseases, emphasizing chronic hepatitis B and other conditions.
How was pevifoscorvir sodium developed?
Pevifoscorvir sodium originated from intellectual property from Dr. Raymond Schinazi's lab and was further optimized by Aligos Therapeutics.
When can we expect more data on the drug?
Further data on the Phase 2 B-Supreme study is expected to be released in the near future, with interim results projected for 2026.
How can I contact Aligos Therapeutics?
For inquiries, you can reach Aligos Therapeutics through their investor relations contact: Jordyn Tarazi, at +1 (650) 910-0427 or via email.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.